Nursing Management for the Successful Application of the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy (212)

11:15 am – 12:15 pm Friday, August 18

1CH  Immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a promising modality of treatment for patients with relapsed or refractory (R/R) malignancy. CAR T cells are patient-derived T cells that are genetically modified ex vivo, using a retroviral vector, to specifically target cancer antigens on the surface of malignant cells.

Most notable is the successful clinical application for patients with R/R B-cell acute lymphoblastic leukemia (B-ALL) when targeting the B cell antigen CD19. Key to the successful application of CAR T cells immunotherapy is identifying patients with appropriate target antigen expression, coordinating T cell collection to maximize T cell yield, developing standardized procedures for infusion of CAR T cells, and managing/preventing toxicities following CAR T cell infusion.